GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2008

Dr. Reddy’s Picks Up Part of Dowpharma’s Small Molecule Franchise Based in U.K.

  • Dr. Reddy’s plans to purchase a segment of Dowpharma’s small molecule business. Dr. Reddy’s also gains a nonexclusive license to Dow’s Pfenex Expression Technology™ for biocatalysis development. The agreements will give Dr. Reddy’s expanded capabilities to provide custom pharmaceutical services.

    The acquisition includes facilities in Mirfield and Cambridge, which are both in the U.K. “The proprietary chiral and biocatalysis technology at the Cambridge site and the scale-up capability in the Mirfield site will add significant value to the company,” points out Satish Reddy, managing director and COO. “This acquisition will also bring strengths in industrial synthesis of complex prostaglandins and carbohydrate chemistry.”

    The transaction is scheduled to close on April 30. Dr. Reddy’s will gain business, customer contracts, associated products, process technology, intellectual property, trademarks, and the transfer of the U.K. centers.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?